8-K: Invivyd Reports Strong Q4 2025 Revenue, VYD2311 Trial Progress

Invivyd, Inc. announced robust fourth-quarter and full-year 2025 financial results, highlighted by significant PEMGARDA revenue growth and rapid advancement of its pivotal VYD2311 clinical trial.

Summary

• Achieved $17.2 million in PEMGARDA net product revenue for Q4 2025, marking a 25% year-over-year and 31% quarter-over-quarter increase.
• Full-year 2025 PEMGARDA net product revenue reached $53.4 million, more than double the $25.4 million reported in 2024.
• Ended 2025 with $226.7 million in cash and cash equivalents, bolstered by over $200 million raised in the second half of 2025.
• The DECLARATION Phase 3 pivotal clinical trial for VYD2311, a vaccine-alternative antibody for COVID prevention, has achieved full enrollment.
• Top-line data for the DECLARATION trial is anticipated by mid-2026.
• The FDA granted Fast Track designation for VYD2311 in December 2025.
• Invivyd received FDA alignment for the LIBERTY Phase 3 clinical trial, which will compare VYD2311 to mRNA COVID vaccines.
• Plans are underway to initiate a Phase 2 clinical trial for VYD2311 in individuals with Long COVID or COVID vaccine injury by mid-2026.
• Selected VBY329 as a potential best-in-class Respiratory Syncytial Virus (RSV) antibody candidate, targeting IND readiness in 2H 2026.
• Appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer.
• Net loss significantly reduced to $52.5 million for 2025, compared to $169.9 million in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by robust revenue growth for PEMGARDA, significant progress in the VYD2311 clinical program including Fast Track designation and full enrollment, and a substantial reduction in net loss, all while expanding its pipeline and strengthening its cash position.

Positives

• PEMGARDA net product revenue grew 25% year-over-year in Q4 2025 to $17.2 million and 31% quarter-over-quarter.
• Full-year 2025 PEMGARDA net product revenue more than doubled to $53.4 million from $25.4 million in 2024.
• Strong cash position of $226.7 million at year-end 2025, following successful capital raises of over $200 million in 2H 2025.
• DECLARATION Phase 3 clinical trial for VYD2311 achieved full enrollment rapidly and is on track for top-line data mid-2026.
• VYD2311 received FDA Fast Track designation, potentially expediting development and review.
• Independent Data Monitoring Committee (IDMC) recommended expanding DECLARATION trial eligibility to include pregnant and breastfeeding women, indicating a positive safety profile review.
• Significant reduction in net loss for 2025 to $52.5 million from $169.9 million in 2024, and net loss per share to $0.30 from $1.43.
• R&D expenses decreased substantially to $38.3 million in 2025 from $137.3 million in 2024, reflecting financial discipline.
• Pipeline expansion with the selection of VBY329, a potential best-in-class RSV antibody candidate, targeting a multi-billion dollar market.
• Appointment of distinguished scientist and physician Michael Mina, M.D., Ph.D., as Chief Medical Officer strengthens leadership.

Negatives

• Selling, General & Administrative (SG&A) expenses increased to $66.9 million for 2025 from $63.4 million in 2024, primarily due to personnel-related costs.
• The company still reported a net loss of $52.5 million for the year ended December 31, 2025.

Risks

• Uncertainties regarding future costs, expenses, revenue, capital requirements, and the need for additional financing.
• Uncertainties regarding market acceptance, payor coverage and reimbursement, or future revenue generated by any authorized or approved product.
• The duration and potential revision or revocation of the Emergency Use Authorization (EUA) for PEMGARDA.
• Ability to maintain an acceptable safety, tolerability, and efficacy profile of any product candidate post-authorization or approval.
• Success of the in-house sales force and ability to expand sales, marketing, and distribution capabilities.
• Changes in expected or existing competition and the regulatory environment.
• Uncertainties related to the regulatory authorization or approval process and available development pathways.
• Whether preclinical candidates are suitable for clinical development.
• Timing, progress, and results of discovery, preclinical, and clinical development activities, including trial enrollment and event accumulation rates.
• Potential clinical trial up-sizing decisions and their timing.
• Unexpected safety or efficacy data from studies or trials.
• Risk that nonclinical or clinical trial results may not be predictive of future results, and interim data are subject to further analysis.
• Ability to generate data for a potential Biologics License Application (BLA) submission for VYD2311.
• Potential variability in neutralizing activity of product candidates across different assays.
• Variability of results in models and methods used to predict activity against SARS-CoV-2 variants.
• Whether target epitopes remain intact and product candidates sustain neutralizing activity against major SARS-CoV-2 variants, especially with viral evolution.
• Risk that lack of awareness of mAb therapies and regulatory scrutiny may adversely impact the development or commercial success of the company's product candidates.
• Reliance on third parties.
• Whether anticipated benefits of the company's partnership with Lindsey Vonn are realized.
• Complexities of manufacturing mAb therapies.
• Macroeconomic and political uncertainties.
• The company's ability to continue as a going concern.
• Adequacy of funding to meet future operating expenses and capital expenditure requirements.

Future Outlook

Invivyd anticipates top-line data from its DECLARATION Phase 3 clinical trial for VYD2311 by mid-2026 and expects to initiate a Phase 2 trial for VYD2311 in Long COVID by mid-2026. The company plans to advance its RSV antibody candidate, VBY329, toward IND readiness in the second half of 2026 and provide an update on a measles antibody candidate in the first half of 2026. Management believes current cash and cash equivalents are sufficient to support ongoing clinical trials, potential VYD2311 commercialization, and pipeline development.

Management Comments

• "With potential commercialization of VYD2311 on the horizon, we are encouraged by continued commercial execution and appeal for monoclonal antibody prophylaxis demonstrated by revenue of PEMGARDA (pemivibart) more than doubling year over year, while operating expenses were reduced by nearly half." Bill Duke, Chief Financial Officer.
• "While we are pleased with Invivyd's ability to exhibit financial discipline, we are most excited about the positive momentum behind VYD2311 and that our recent capital raises enable us to invest in the ongoing DECLARATION pivotal clinical trial and potential commercialization, if approved, in addition to our other pipeline programs." Bill Duke, Chief Financial Officer.
• "2026 is off to a busy start as we execute our pivotal VYD2311 program, expand our pipeline of monoclonal antibodies, and educate key stakeholders about the role monoclonal antibodies can and should play in the prevention of critical infectious diseases, beginning with COVID." Marc Elia, Chairman of the Invivyd Board of Directors.
• "We are pleased with the progress we've made and remain focused on creating medical value for patients and shareholders with molecules that can complement, provide alternative to, or synergize with vaccination across multiple pathogens. We look forward to sharing additional updates throughout the year." Marc Elia, Chairman of the Invivyd Board of Directors.

Industry Context

StockSavvy.ai notes that Invivyd's focus on monoclonal antibodies for infectious disease prevention, particularly COVID-19 and RSV, positions it within a growing segment of the biopharmaceutical market seeking alternatives or complements to traditional vaccines. The emphasis on patient-friendly administration (IM dosing for VYD2311) and addressing unmet needs in immunocompromised populations, Long COVID, and vaccine injury aligns with evolving healthcare demands. The expansion into RSV prophylaxis, a market projected to reach $3-$4 billion by 2030, indicates a strategic diversification beyond SARS-CoV-2, mirroring broader industry trends towards multi-pathogen platforms.

Comparison to Industry Standards

• The DECLARATION trial's rapid full enrollment for VYD2311, with top-line data expected mid-2026, suggests efficient trial execution, which can be a competitive advantage in the fast-paced infectious disease space compared to slower-moving trials by some larger pharmaceutical companies.
• The FDA's Fast Track designation for VYD2311 indicates recognition of its potential to address an unmet medical need, placing it in a favorable regulatory position similar to other expedited programs for critical therapies.
• The significant reduction in R&D expenses from $137.3 million in 2024 to $38.3 million in 2025, while advancing multiple clinical programs, demonstrates a strong focus on cost efficiency, which is crucial for biotech companies, especially when compared to the often higher burn rates of early-stage competitors.
• The company's strategy to evaluate VYD2311 against mRNA COVID vaccines in the LIBERTY trial directly addresses a key comparative question in the market, similar to how other novel therapies are often benchmarked against established standards of care.

Management Changes

Related Party Transactions

• Accrued expenses include related-party amounts of $703 thousand for 2025 (compared to $1,274 thousand for 2024).
• Cost of product revenue includes related-party amounts of $2,137 thousand for 2025 (compared to $1,027 thousand for 2024).
• Research and development expenses include related-party amounts of $4,557 thousand for 2025 (compared to $4,546 thousand for 2024).

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reduced net loss, successful capital raise, and significant progress in clinical pipeline, potentially increasing shareholder value.
• Patients (Immunocompromised, Long COVID, etc.): Potential for new prophylactic and therapeutic options for COVID-19 (VYD2311, PEMGARDA) and RSV (VBY329), offering improved protection and treatment.
• Employees: Increased personnel-related costs suggest growth in the workforce, potentially positive for employment. Appointment of a new CMO indicates strategic leadership strengthening.
• Customers (Healthcare Providers): Continued commercial execution and appeal for monoclonal antibody prophylaxis, with an expanding commercial team and market access strategy for PEMGARDA and future products.
• Creditors: Improved financial health with a strong cash position and reduced net loss could enhance creditworthiness.

Next Steps

• Potential decision on DECLARATION trial up-sizing in approximately April 2026.
• Top-line data from DECLARATION Phase 3 clinical trial expected mid-2026.
• Initiation of LIBERTY Phase 3 clinical trial (VYD2311 vs mRNA COVID vaccine) with study design being finalized for a target mid-year start.
• Initiation of Phase 2 clinical trial for VYD2311 in Long COVID or COVID vaccine injury expected by mid-2026.
• Update on selection of a preclinical measles monoclonal antibody candidate in the first half of 2026.
• Advancement of VBY329 (RSV antibody) toward IND readiness in 2H 2026.
• Launch of national multimedia educational campaign with Lindsey Vonn in early Spring 2026.
• Management to host a conference call on March 5, 2026, at 8:30 AM ET.

Key Dates

Recommendation

The filing presents a highly compelling investment case, demonstrating robust financial performance with significant revenue growth for PEMGARDA and a dramatic reduction in net loss. Critically, the rapid advancement of the pivotal VYD2311 clinical trial, including full enrollment and Fast Track designation, de-risks a key pipeline asset with substantial market potential. The strong cash position, strategic pipeline expansion into RSV, and strengthened management team further underscore the company's positive trajectory and future growth prospects, making it a strong buy for investors seeking exposure to innovative biopharmaceutical solutions for infectious diseases.

Keywords

Invivyd, IVVD, PEMGARDA, VYD2311, COVID-19, Monoclonal Antibody, Clinical Trial, DECLARATION, Fast Track, FDA, Biotechnology, Pharmaceuticals, RSV, VBY329, Financial Results, Biologics, Vaccine Alternative, Immunocompromised, Long COVID, Corporate Presentation